These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

791 related items for PubMed ID: 17452609

  • 1. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S.
    Circulation; 2007 May 08; 115(18):2398-409. PubMed ID: 17452609
    [Abstract] [Full Text] [Related]

  • 2. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY, Ko SK, Liew D.
    Clin Ther; 2009 Dec 08; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [Abstract] [Full Text] [Related]

  • 3. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
    Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P.
    Clin Ther; 2007 Feb 08; 29(2):253-60. PubMed ID: 17472818
    [Abstract] [Full Text] [Related]

  • 4. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
    Greving JP, Visseren FL, de Wit GA, Algra A.
    BMJ; 2011 Mar 30; 342():d1672. PubMed ID: 21450800
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.
    Can J Clin Pharmacol; 2009 Mar 30; 16(2):e331-45. PubMed ID: 19531812
    [Abstract] [Full Text] [Related]

  • 6. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.
    Henriksson M, Epstein DM, Palmer SJ, Sculpher MJ, Clayton TC, Pocock SJ, Henderson RA, Buxton MJ, Fox KA.
    Heart; 2008 Jun 30; 94(6):717-23. PubMed ID: 18032459
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy.
    Lee KK, Cipriano LE, Owens DK, Go AS, Hlatky MA.
    Circulation; 2010 Oct 12; 122(15):1478-87. PubMed ID: 20876434
    [Abstract] [Full Text] [Related]

  • 8. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D, Park HJ, Ko SK.
    Clin Ther; 2009 Oct 12; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Oct 12; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW, Huse DM, Miller JD, Kraemer DF, Hartz SC.
    Can J Clin Pharmacol; 2001 Oct 12; 8(1):9-16. PubMed ID: 11283756
    [Abstract] [Full Text] [Related]

  • 13. Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial.
    Mark DB, Knight JD, Cowper PA, Davidson-Ray L, Anstrom KJ.
    Am Heart J; 2008 Oct 12; 156(4):698-705. PubMed ID: 18926150
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of captopril therapy after myocardial infarction.
    Tsevat J, Duke D, Goldman L, Pfeffer MA, Lamas GA, Soukup JR, Kuntz KM, Lee TH.
    J Am Coll Cardiol; 1995 Oct 12; 26(4):914-9. PubMed ID: 7560617
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
    van Hout BA, Simoons ML.
    Eur Heart J; 2001 May 12; 22(9):751-61. PubMed ID: 11350107
    [Abstract] [Full Text] [Related]

  • 16. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.
    Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR, IDEAL Investigators.
    J Am Coll Cardiol; 2009 Dec 15; 54(25):2353-7. PubMed ID: 20082922
    [Abstract] [Full Text] [Related]

  • 17. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
    Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E, PROVE IT-TIMI 22 Investigators.
    J Am Coll Cardiol; 2005 Oct 18; 46(8):1405-10. PubMed ID: 16226162
    [Abstract] [Full Text] [Related]

  • 18. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV, Frick KD, Wade A, Simko R, Burge R.
    Clin Ther; 2009 Apr 18; 31(4):862-79. PubMed ID: 19446159
    [Abstract] [Full Text] [Related]

  • 19. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P, Stenestrand U, Malmberg K, Jönsson B.
    Clin Ther; 2005 Jan 18; 27(1):100-10. PubMed ID: 15763611
    [Abstract] [Full Text] [Related]

  • 20. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L, Engelfriet P, Jacobs-van der Bruggen MA, Hoogenveen RT, Boshuizen HC, Verschuren MW.
    Eur J Cardiovasc Prev Rehabil; 2009 Jun 18; 16(3):371-6. PubMed ID: 19305351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.